A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma

Background The therapeutic effect of immune checkpoint blockers, especially the neutralizing antibodies of programmed cell death (PD-1) and its ligand programmed death ligand 1 (PD-L1), has been well verified in melanoma. Nevertheless, the dissatisfactory response rate and the occurrence of resistan...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lin Liu, Chen Yu, Jingjing Ma, Weinan Guo, Jinyuan Ma, Sen Guo, Huina Wang, Sijia Wang, Qiong Shi, Tao Zhao, Fengfan Yang, Shuyang Chen, Jianru Chen, Jianhong Zhao, Xiuli Yi, Yuqi Yang, Qingrong Ni, Guannan Zhu, Tianwen Gao, Chunying Li
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001866.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanoma
by: Yuehua Li, et al.
Published: (2025-01-01)

Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study
by: Bolun Zhao, et al.
Published: (2024-08-01)

Distributed GRS‐coded differential spatial modulation for half‐duplex cooperative network based on relay optimization and joint decoding
by: Chen Chen, et al.
Published: (2024-12-01)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
by: Yu Chen, et al.
Published: (2023-01-01)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
by: Diwakar Davar, et al.
Published: (2015-01-01)

Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes
by: Gwenann Cadiou, et al.
Published: (2024-12-01)

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
by: Nathalie Labarrière, et al.
Published: (2020-05-01)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
by: Yago Pico de Coaña, et al.
Published: (2020-05-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA
by: Dong Yang, et al.
Published: (2020-10-01)

Downregulating LKB1 in bone marrow mesenchymal stem cells could inhibit CD4+ T cell proliferation via the PD-1/PD-L1 signaling pathway
by: Yaqin Zhang, et al.
Published: (2024-11-01)

Extra-cranial radiotherapy in anti-PD-1-treated melanoma patients: A systematic review
by: Philippe Saiag, et al.
Published: (2024-12-01)

Prognostic and Predictive Non-Invasive Biomarkers in Cutaneous Melanoma Treated With Anti PD-1 Antibodies
by: S. Torres-Martínez, et al.
Published: (2023-11-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
by: Xue Wang, et al.
Published: (2025-01-01)

SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis
by: Fanghui Chen, et al.
Published: (2025-01-01)

CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma
by: Jiaojiao Xu, et al.
Published: (2025-01-01)

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma
by: Teitur Sævarsson, et al.
Published: (2024-12-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
by: Grant R Williams, et al.
Published: (2020-10-01)

Lightweight UAV Small Target Detection and Perception Based on Improved YOLOv8-E
by: Yongjuan Zhao, et al.
Published: (2024-11-01)

Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient
by: P. Kissoonsingh, et al.
Published: (2022-01-01)

Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma
by: Kim Koczka, et al.
Published: (2023-02-01)

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Jin Bian, et al.
Published: (2022-01-01)

AIEgen-self-assembled nanoparticles with anti-PD-L1 antibody functionalization realize enhanced synergistic photodynamic therapy and immunotherapy against malignant melanoma
by: Lu Li, et al.
Published: (2025-02-01)

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights
by: Juan Li, et al.
Published: (2025-02-01)

Living photosynthetic microneedle patches for in situ oxygenation and postsurgical melanoma therapy
by: Jinxuan Jia, et al.
Published: (2024-11-01)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
by: Dirk Schadendorf, et al.
Published: (2020-10-01)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
by: Stijn L W Koolen, et al.
Published: (2020-10-01)

The PD-1 with PD-L1 Axis Is Pertinent with the Immune Modulation of Atrial Fibrillation by Regulating T Cell Excitation and Promoting the Secretion of Inflammatory Factors
by: Guodong Chang, et al.
Published: (2022-01-01)

PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity
by: Heng Zhang, et al.
Published: (2025-01-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
by: Caner Acar, et al.
Published: (2024-12-01)

Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma
by: Chun Wai Wong, et al.
Published: (2025-01-01)

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
by: Thierry Passeron, et al.
Published: (2021-06-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy
by: Zhishui Chen, et al.
Published: (2024-01-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01)

PD-1 deficiency impairs eosinophil recruitment to tissue during Trichinella spiralis infection
by: Yiqi Liu, et al.
Published: (2024-12-01)